Levossimendano Ever Pharma (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, enhancing myocardial contractility without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering afterload, which together improve cardiac output.

The dosage of Levossimendano Ever Pharma is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, reducing the risk of arrhythmias. Its vasodilatory effect also lowers afterload, offering a dual mechanism that can be advantageous over agents that solely increase heart rate or contractility.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the intravenous solution and discard any unused portion after the recommended in‑use period.

Levossimendano Ever Pharma is administered intravenously, typically as a loading infusion followed by a continuous maintenance infusion. Administration is performed under continuous cardiac and haemodynamic monitoring in a hospital setting.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood pressure changes, cardiac rhythm disturbances, and signs of allergic response throughout the infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving concurrent potent vasodilators that could precipitate dangerous blood pressure drops. Caution is also advised in severe hepatic impairment.